Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) Q3 2019 Earnings Conference Call November 6, 2019 4:30 PM ET Company Participants Jim Kelly – Executive Vice President and Chief Financial Officer Mihales Polymeropoulos – President and Chief Executive Officer Tim Williams – General Counsel Conference Call Participants Roger Song – Jefferies Joel Beatty – Citi Jason Butler – JMP Securities Derek Archila – Stifel Operator Ladies and gentlemen, thank you for standing by, and welcome to the Third Quarter 2019 Vanda Pha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Securities regist ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware (State or oth ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2019 Earnings Conference Call July 31, 2019 4:30 PM ET Company Participants James Kelly - Chief Financial Officer Mihael Polymeropoulos - President and Chief Executive Officer Conference Call Participants Roy Buchanan - JMP Securities LLC Chris Howerton - Jefferies Group LLC Joel Beatty - Citigroup Inc. Derek Archila - Stifel Financial Corp. Operator Good day, ladies and gentlemen, and welcome to Vanda Pharmaceuticals’ Second Quarter 2019 Earnings Conference call. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) (State or other juris ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2019 Results Earnings Conference Call May 1, 2019 4:30 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer, Treasurer Mihael Polymeropoulos - President and Chief Executive Officer Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Derek Archila - Stifel Esther Rajavelu - Oppenheimer Operator Good day ladies and gentlemen and welcome to the Vanda Pharmaceuticals' first quarter 2019 earnings conference cal ...

CORPORATE PRESENTATION 2019 March 11, 2019 Forward-Looking Statements Various statements in this presentation, including, but not limited to, Vanda's financial guidance for 2019, are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements in ...

ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organizat ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2018 Earnings Conference Call February 13, 2019 4:30 PM ET Company Participants James Kelly - EVP and CFO Mihael Polymeropoulos - President and CEO Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Jason Butler - JMP Securities Pete Stavropoulos - Cantor Fitzgerald Esther Rajavelu - Oppenheimer Derek Archila - Stifel Operator Good day ladies and gentlemen and welcome to the Vanda Pharmaceutical’s fourth quarter 2018 earnings conference ca ...